Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience

Abstract Introduction Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for diabetic macular edema (DME). We investigated the effect of initial glycosylated hemoglobin (HbA1c) level and glomerular filtration rate (GFR) on treatment outcomes in patients with DME recei...

Full description

Bibliographic Details
Main Authors: Eloi Debourdeau, Robin Medard, Chloe Chamard, Vuong Nguyen, Pierre Henry Gabrielle, Catherine Creuzot-Garcher, Sandrine Allieu, Mark C. Gillies, Daniel Barthelmes, Vincent Daien, the Fight Retinal Blindness! Study Group
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-07-01
Series:Ophthalmology and Therapy
Subjects:
Aflibercept
Diabetic macular edema
Intraocular injection
Ranibizumab
Systemic factors
Online Access:https://doi.org/10.1007/s40123-023-00758-1

Similar Items

Similar Items